These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 24843540)

  • 1. Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.
    Matsumura T; Taketa K; Shimoda S; Araki E
    J Diabetes Investig; 2012 Feb; 3(1):11-23. PubMed ID: 24843540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins meditate anti-atherosclerotic action in smooth muscle cells by peroxisome proliferator-activated receptor-γ activation.
    Fukuda K; Matsumura T; Senokuchi T; Ishii N; Kinoshita H; Yamada S; Murakami S; Nakao S; Motoshima H; Kondo T; Kukidome D; Kawasaki S; Kawada T; Nishikawa T; Araki E
    Biochem Biophys Res Commun; 2015 Jan; 457(1):23-30. PubMed ID: 25529449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
    Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
    Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
    Ishii N; Matsumura T; Kinoshita H; Fukuda K; Motoshima H; Senokuchi T; Nakao S; Tsutsumi A; Kim-Mitsuyama S; Kawada T; Takeya M; Miyamura N; Nishikawa T; Araki E
    Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1598-605. PubMed ID: 20508203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
    Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
    Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages.
    Yano M; Matsumura T; Senokuchi T; Ishii N; Murata Y; Taketa K; Motoshima H; Taguchi T; Sonoda K; Kukidome D; Takuwa Y; Kawada T; Brownlee M; Nishikawa T; Araki E
    Circ Res; 2007 May; 100(10):1442-51. PubMed ID: 17463321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome.
    Bähr IN; Tretter P; Krüger J; Stark RG; Schimkus J; Unger T; Kappert K; Scholze J; Parhofer KG; Kintscher U
    Hypertension; 2011 Oct; 58(4):725-32. PubMed ID: 21876071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
    Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
    Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
    Collins AR; Meehan WP; Kintscher U; Jackson S; Wakino S; Noh G; Palinski W; Hsueh WA; Law RE
    Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):365-71. PubMed ID: 11231915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
    Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
    Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of peroxisome proliferator-activated receptor γ on angiotensin II type 1 receptor-mediated insulin sensitivity, vascular inflammation and atherogenesis in hypercholesterolemic mice.
    Tiyerili V; Becher UM; Camara B; Yildirimtürk C; Aksoy A; Kebschull M; Werner N; Nickenig G; Müller C
    Arch Med Sci; 2015 Aug; 11(4):877-85. PubMed ID: 26322101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes.
    Pang T; Benicky J; Wang J; Orecna M; Sanchez-Lemus E; Saavedra JM
    J Hypertens; 2012 Jan; 30(1):87-96. PubMed ID: 22124178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
    Mukherjee R; Hoener PA; Jow L; Bilakovics J; Klausing K; Mais DE; Faulkner A; Croston GE; Paterniti JR
    Mol Endocrinol; 2000 Sep; 14(9):1425-33. PubMed ID: 10976920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Peroxisome Proliferator-Activated Receptor Gamma and Atherosclerosis: Post-translational Modification and Selective Modulators.
    Yin L; Wang L; Shi Z; Ji X; Liu L
    Front Physiol; 2022; 13():826811. PubMed ID: 35309069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
    Schupp M; Janke J; Clasen R; Unger T; Kintscher U
    Circulation; 2004 May; 109(17):2054-7. PubMed ID: 15117841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARgamma activity in the vessel wall: anti-atherogenic properties.
    Reiss AB; Vagell ME
    Curr Med Chem; 2006; 13(26):3227-38. PubMed ID: 17168709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro Screening and Evaluation of 37 Traditional Chinese Medicines for Their Potential to Activate Peroxisome Proliferator-Activated Receptors-γ.
    Gao D; Zhang Y; Yang F; Lin Y; Zhang Q; Xia Z
    Pharmacogn Mag; 2016; 12(46):120-7. PubMed ID: 27076748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.
    Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL
    J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
    Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
    Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
    Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.